Navigation Links
Ferring Announces It Will Present Phase 3 Data for Cervical Ripening Agent at American College of Obstetricians and Gynecologists Annual Clinical Meeting
Date:5/2/2013

NEW ORLEANS, May 2, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present efficacy and safety data from its Phase 3 EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 61st annual clinical meeting of the American College of Obstetricians and Gynecologists in New Orleans, May 4 – 8, 2013.

Studies accepted for presentation include:

  • A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Reduced Time to Delivery and Significantly Less Antibiotic Use" (lead author: Deborah A. Wing , M.D.; University of California, Irvine; Irvine, CA); and
  • A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Misoprostol Vaginal Insert Reduces Time to Delivery in Nulliparous and Parous Women" (lead author: R. Lamar Parker , M.D.; Lyndhurst Clinical Research, Winston-Salem, NC).

*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of EXogenous Prostaglandin comparing the Efficacy and safety of the MVI 200 mcg to the Dinoprostone vaginal Insert for reducing Time to vaginal delivery in pregnant women at tErm.

For further information, contact:
Leila Boukassi
MSL New York
Leila.Boukassi@mslgroup.com; 646.500.7735

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
3. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Halyard Health, Inc. (NYSE: HYH ) today reported ... outlook and related key planning assumptions. Executive Summary ... percent increase compared to the prior year. ... compared to net income of $15 million in the fourth ... million compared to adjusted net income of $27 million in ...
(Date:2/27/2017)... 2017 Mederi Therapeutics today announced the ... 2468 patients who received  Stretta Therapy  to treat ... Systematic Review and Meta-Analysis of Controlled and Prospective ... of Gastroesophageal Reflux Disease ", was published in ... , MD, head of the Esophageal and Swallowing ...
(Date:2/27/2017)... --  Royal Philips (NYSE: PHG ... technology, today announced 510(k) clearance from the U.S. ... ElastQ Imaging capability, further expanding the functionalities of ... enables simultaneous imaging of tissue and assessment of ... of various liver conditions. With ElastQ Imaging, clinicians ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution ... staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to a ... , Previous studies have provided evidence of a link between pesticides and incidence ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist , ... office, Antoine Dental Center. Currently, patients can get single dental implants for $3,599 ... patients can learn more about these offers by contacting Antoine Dental Center. Both ...
(Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid ... explain why susceptibility to one of the disorders could place individuals at lower risk ... journal npj Schizophrenia. , “There is a wealth of genomic data on both ...
(Date:2/24/2017)... ... 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses ... not if you will be attacked, but when.” However, he and many others involved ... care. , Improvements in auditing and monitoring have taken security in health care a ...
Breaking Medicine News(10 mins):